TrialsgrambetaRCTs are beautiful

PLATO

2009

Platelet Inhibition and Patient Outcomes

In 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.

Result

Efficacy: CV death, MI or stroke at 12 monthsHR 0.84

Below 1 favours ticagrelor, above 1 favours clopidogrel.

Event rates
Absolute difference
1.9 points

The absolute difference is derived from the event rates.

Also reported: All-cause mortality also reduced.

Original publication
Subtopic
Antiplatelets
Design
Double-blind RCT, 12 mo
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Wallentin L, et al. N Engl J Med. 2009;361(11):1045-1057.doi 10.1056/NEJMoa0904327

Discussion & critique

Regional heterogeneity (notably worse outcomes in the US sites) prompted FDA scrutiny: attributed to higher aspirin doses. Dyspnoea and bradycardia are notable adverse signals.

Discussed in podcasts